Senores Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nzq7djoxc6xtw6wu33brlv6c.pdf

Key Takeaways


ANDA Portfolio & Launch Visibility

Shah: “For FY27, our initial outlook indicates revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60%. This confidence is supported by a robust order pipeline and clear visibility on upcoming product launches over the coming quarters.”

Apnar Pharma Integration

Shah: “So, for the full year, we expect Apnar to give us about INR80 crores to INR100 crores of revenues from that particular plant. And that has already started giving us from this last month onwards.”

Emerging Markets Turnaround

Shah: “Probably once we cross about INR220 crores to INR250 crores, then you will probably see another 200 basis points, 300 basis points jump in emerging market margins.”

US Strategy & Front-End Buildout

Shah: “As a company, we are building at least INR2,500 crores to INR3,000 crores of revenue just coming out of the US in the next three to four years’ timeframe.”

Margins, Mix & Working Capital

Majmudar: “In today’s scenario, to talk about 35% growth is itself very courageous, I would say. But I think we have enough visibility to at least say that this could be regarded as the minimum achievable.”

India Branded Generics & Other Bets


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth30% to 40% YoYFY27
PAT growth50% to 60% YoYFY27
Blended EBITDA margin29% to 31%FY27
Apnar Pharma revenue contribution₹80 cr to ₹100 crFY27
Emerging markets revenue~₹180 crFY27
Emerging markets EBITDA marginSustain at 18–19%, settle at 20–21%FY27
ANDA launches30+ approved ANDAs (100+ strengths)Next few quarters
Remaining ANDA commercialization90–95% of 51 ANDAsNext 6–8 quarters
PIC/S approval for emerging market facilityApproval obtainedJune/July 2026
Apnar remaining 25% stake acquisitionStake acquiredBy end of this year
Amerisyn JV revenue₹70–80 cr average (range ₹50–100 cr)FY27
Amerisyn JV EBITDA profitabilityUpwards of 40%FY27
FY27 capex~₹200 cr (₹100 cr injectables, ₹100 cr other)FY27
Normalized tax rate~23% averageOngoing
Capacity expansion decision (4th OSD line location)Decision madeNext two quarters

Key Metrics

MetricQ4 FY26
Consolidated revenue₹190 cr, +66% YoY
Consolidated EBITDA₹62 cr, >3x YoY
EBITDA margin32.7%, +1,151 bps YoY
PAT after tax and minority interest~₹32 cr, +78% YoY
FY26 consolidated revenue₹664 cr, +62% YoY
FY26 consolidated EBITDA~₹200 cr, more than doubled YoY
FY26 EBITDA margin30%, +527 bps YoY
FY26 PAT after tax and minority interest₹122 cr, +108% YoY
FY26 operating cash flow~₹75 cr, significant improvement over last year
FY27 revenue growth guidance30% to 40%
FY27 PAT growth guidance50% to 60%
FY27 EBITDA margin guidance29% to 31%
Regulated markets revenue₹118 cr, +83% YoY
Emerging markets revenue₹20 cr, +26% YoY
India branded generics revenue~₹9 cr, doubled YoY
Approved ANDAs51, covering >150 product strengths, up from 22 in March 2025
ANDAs commercially launched20 launched; 30 approved ANDAs covering >100 strengths to be launched over next few quarters
Molecules under development~27 molecules, involving >60 strengths
Working capital days187 days; ex-Apnar ~104 days
Apnar Pharma expected FY27 revenue₹80 cr to ₹100 cr
Emerging markets FY27 revenue projection~₹180 cr
Emerging markets Q4 EBITDA margin18% to 19%
CDMO-CMO revenue share47% to 48% of total; own products 50% to 53%
FY26 capex~₹230 cr, including ~₹65 cr for ANDA acquisition
FY27 expected capex~₹200 cr, including ₹100 cr for injectable and ₹100 cr for other plants and maintenance
Amerisyn JV FY27 revenue budget₹70 cr to ₹80 cr on average